Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients
Ayodele Alaiya,1 Abeer Alshukairi,2 Zakia Shinwari,1 Mariam AL-Fares,3 Jawaher Alotaibi,4 Waleed AlOmaim,3 Ibtihaj Alsharif,5 Razan Bakheet,6 Layla Alharbi,5 Rabab Allam,1 Ayed Asiri,7 Ziad Memish,8 Khaldoun Alromaih,6 Maha Al-Mozaini5 1Proteomics Unit, Stem Cell and Tissue Re-Engineering Program, K...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/aa02c58f33004c658c030616562bfc1c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:aa02c58f33004c658c030616562bfc1c |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
covid-19 sars-cov mers-cov expression proteomics biomarkers Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
covid-19 sars-cov mers-cov expression proteomics biomarkers Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Alaiya A Alshukairi A Shinwari Z AL-Fares M Alotaibi J AlOmaim W Alsharif I Bakheet R Alharbi L Allam R Asiri A Memish Z Alromaih K Al-Mozaini M Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients |
| description |
Ayodele Alaiya,1 Abeer Alshukairi,2 Zakia Shinwari,1 Mariam AL-Fares,3 Jawaher Alotaibi,4 Waleed AlOmaim,3 Ibtihaj Alsharif,5 Razan Bakheet,6 Layla Alharbi,5 Rabab Allam,1 Ayed Asiri,7 Ziad Memish,8 Khaldoun Alromaih,6 Maha Al-Mozaini5 1Proteomics Unit, Stem Cell and Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia; 2Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia; 3Clinical Chemistry Laboratory, Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 4Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia; 5Immunocompromised Host Research Unit, Department of Infection and Immunity, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 6Centre for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia; 7Critical Care Services, Al Imam Abdulrahman Al Faisal Hospital, Riyadh, Kingdom of Saudi Arabia; 8Research and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh, Kingdom of Saudi ArabiaCorrespondence: Ayodele AlaiyaProteomics Unit, Stem Cell and Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Centre, KFSH&RC, BOX 3354, Riyadh, 11211, Saudi ArabiaTel +966 114424178Email aalaiya@kfshrc.edu.saMaha Al-MozainiImmunocompromised Host Research Unit, Department of Infection and Immunity, KFSH&RC, Riyadh, Saudi ArabiaTel +966 114439632Email mmozaini@kfshrc.edu.saPurpose: This study aimed to understand the pathophysiology of host responses to infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) and Middle East respiratory syndrome coronavirus (MERS-CoV) and to identify proteins for patient stratification with different grades of illness severity.Patients and Methods: Peripheral blood samples from 43 patients with different grades of COVID-19, 7 MERS-CoV patients admitted to the ICU, and 10 healthy subjects were analyzed using label-free quantitative liquid chromatography–mass spectrometry (LC–MS).Results: We identified 193 and 91 proteins that differed significantly between COVID-19 and MERS-CoV sample groups, respectively, and 49 overlapped between datasets. Only 10 proteins are diagnostic of asymptomatic cases, 12 are prognostic of recovery from severe illness, and 28 are prognostic of a fatal outcome of COVID-19. These proteins are implicated in virus-specific/related signaling networks. Notable among the top canonical pathways are humoral immunity, inflammation, acute-phase response signaling, liver X receptor/retinoid X receptor (LXR/RXR) activation, coagulation, and the complement system. Furthermore, we confirmed positive viral shedding in 11.76% of 51 additional peripheral blood samples, indicating that caution should be taken to avoid the possible risk of transfusion of infected blood products.Conclusion: We identified COVID-19 and MERS-CoV protein panels that have potential as biomarkers and might assist in the prognosis of SARS-CoV-2 infection. The identified markers further our understanding of COVID-19 disease pathophysiology and may have prognostic or therapeutic potential in predicting or managing host cell responses to human COVID-19 and MERS-CoV infections.Keywords: COVID-19, SARS-CoV, MERS-CoV, expression proteomics, biomarkers |
| format |
article |
| author |
Alaiya A Alshukairi A Shinwari Z AL-Fares M Alotaibi J AlOmaim W Alsharif I Bakheet R Alharbi L Allam R Asiri A Memish Z Alromaih K Al-Mozaini M |
| author_facet |
Alaiya A Alshukairi A Shinwari Z AL-Fares M Alotaibi J AlOmaim W Alsharif I Bakheet R Alharbi L Allam R Asiri A Memish Z Alromaih K Al-Mozaini M |
| author_sort |
Alaiya A |
| title |
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients |
| title_short |
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients |
| title_full |
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients |
| title_fullStr |
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients |
| title_full_unstemmed |
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients |
| title_sort |
alterations in the plasma proteome induced by sars-cov-2 and mers-cov reveal biomarkers for disease outcomes for covid-19 patients |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/aa02c58f33004c658c030616562bfc1c |
| work_keys_str_mv |
AT alaiyaa alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alshukairia alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT shinwariz alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alfaresm alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alotaibij alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alomaimw alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alsharifi alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT bakheetr alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alharbil alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT allamr alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT asiria alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT memishz alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT alromaihk alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients AT almozainim alterationsintheplasmaproteomeinducedbysarscov2andmerscovrevealbiomarkersfordiseaseoutcomesforcovid19patients |
| _version_ |
1718387651250225152 |
| spelling |
oai:doaj.org-article:aa02c58f33004c658c030616562bfc1c2021-12-02T15:12:56ZAlterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients1178-7031https://doaj.org/article/aa02c58f33004c658c030616562bfc1c2021-09-01T00:00:00Zhttps://www.dovepress.com/alterations-in-the-plasma-proteome-induced-by-sars-cov-2-and-mers-cov--peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Ayodele Alaiya,1 Abeer Alshukairi,2 Zakia Shinwari,1 Mariam AL-Fares,3 Jawaher Alotaibi,4 Waleed AlOmaim,3 Ibtihaj Alsharif,5 Razan Bakheet,6 Layla Alharbi,5 Rabab Allam,1 Ayed Asiri,7 Ziad Memish,8 Khaldoun Alromaih,6 Maha Al-Mozaini5 1Proteomics Unit, Stem Cell and Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia; 2Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia; 3Clinical Chemistry Laboratory, Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 4Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia; 5Immunocompromised Host Research Unit, Department of Infection and Immunity, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; 6Centre for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia; 7Critical Care Services, Al Imam Abdulrahman Al Faisal Hospital, Riyadh, Kingdom of Saudi Arabia; 8Research and Innovation Center, King Saud Medical City, Ministry of Health, Riyadh, Kingdom of Saudi ArabiaCorrespondence: Ayodele AlaiyaProteomics Unit, Stem Cell and Tissue Re-Engineering Program, King Faisal Specialist Hospital and Research Centre, KFSH&RC, BOX 3354, Riyadh, 11211, Saudi ArabiaTel +966 114424178Email aalaiya@kfshrc.edu.saMaha Al-MozainiImmunocompromised Host Research Unit, Department of Infection and Immunity, KFSH&RC, Riyadh, Saudi ArabiaTel +966 114439632Email mmozaini@kfshrc.edu.saPurpose: This study aimed to understand the pathophysiology of host responses to infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) and Middle East respiratory syndrome coronavirus (MERS-CoV) and to identify proteins for patient stratification with different grades of illness severity.Patients and Methods: Peripheral blood samples from 43 patients with different grades of COVID-19, 7 MERS-CoV patients admitted to the ICU, and 10 healthy subjects were analyzed using label-free quantitative liquid chromatography–mass spectrometry (LC–MS).Results: We identified 193 and 91 proteins that differed significantly between COVID-19 and MERS-CoV sample groups, respectively, and 49 overlapped between datasets. Only 10 proteins are diagnostic of asymptomatic cases, 12 are prognostic of recovery from severe illness, and 28 are prognostic of a fatal outcome of COVID-19. These proteins are implicated in virus-specific/related signaling networks. Notable among the top canonical pathways are humoral immunity, inflammation, acute-phase response signaling, liver X receptor/retinoid X receptor (LXR/RXR) activation, coagulation, and the complement system. Furthermore, we confirmed positive viral shedding in 11.76% of 51 additional peripheral blood samples, indicating that caution should be taken to avoid the possible risk of transfusion of infected blood products.Conclusion: We identified COVID-19 and MERS-CoV protein panels that have potential as biomarkers and might assist in the prognosis of SARS-CoV-2 infection. The identified markers further our understanding of COVID-19 disease pathophysiology and may have prognostic or therapeutic potential in predicting or managing host cell responses to human COVID-19 and MERS-CoV infections.Keywords: COVID-19, SARS-CoV, MERS-CoV, expression proteomics, biomarkersAlaiya AAlshukairi AShinwari ZAL-Fares MAlotaibi JAlOmaim WAlsharif IBakheet RAlharbi LAllam RAsiri AMemish ZAlromaih KAl-Mozaini MDove Medical Pressarticlecovid-19sars-covmers-covexpression proteomicsbiomarkersPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 4313-4328 (2021) |